Scholarlink

Background <p>Glioblastoma is the most aggressive primary brain tumor. Although temozolomide induces DNA damage, its efficacy is limited by intrinsic resistance mechanisms, leading to tumor relapse. In this study we aimed to identify microRNA-mediated resistance mechanisms.</p> Methods <p>MicroRNA screens were performed to identify temozolomide resistance mechanisms. Temozolomide response was evaluated using clonogenic and spheroid assays in glioblastoma cell lines&#xa0;and patient-derived primary cells. DNA damage response was assessed by γH2AX foci formation. Cell cycle distribution, senescence and ferroptosis were assessed following <i>miR-19b</i> attenuation. An orthotopic xenograft and a syngeneic mouse model were used to confirm findings.</p> Results <p>Our screen and subsequent phosphoprotein analysis identified <i>miR-19b</i> and its target PPP2R5E, a subunit of the phosphatase PP2A, as modulators of temozolomide response. Attenuation of <i>miR-19b</i> upregulated PPP2R5E, inducing genotoxic stress, thereby enhancing temozolomide response. Mechanistically, DNA damage correlated with elevated nuclear ROS, promoting senescence and ferroptosis. Consistently, pharmacological activation of PP2A with FTY720 phenocopied the effects of <i>miR-19b</i> suppression. Conversely, knockdown of PPP2R5E reversed temozolomide sensitisation in vitro, in vivo, and ex vivo models, confirming the critical role of the <i>miR-19b</i>/PPP2R5E axis in modulating drug response.</p> Conclusions <p>Therapeutic targeting of the PPP2R5E/PP2A complexes holds promise for enhanced temozolomide efficacy in glioblastoma.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Targeting the miR-19b/PPP2R5E axis enhances temozolomide response in glioblastoma via ROS-induced DNA damage

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月27日

查看全文
  • Elham Kashani,
  • Martin C. Sadowski,
  • Jaison Phour,
  • Ali Hashemi Gheinani,
  • Kristyna Hlavackova,
  • Stefan Haemmig,
  • Ulrich Baumgartner,
  • Nicole Mueller-Wirth,
  • Carmen Trefny,
  • Bushra Sharf Den Abu Fakher,
  • Evelina Parvanova,
  • Coline Nydegger,
  • Theoni Maragkou,
  • Philippe Schucht,
  • Aurel Perren,
  • Pascal Zinn,
  • Markus Lüdi,
  • Thomas Michael Marti,
  • Philippe Krebs,
  • Erik Vassella

摘要

Background

Glioblastoma is the most aggressive primary brain tumor. Although temozolomide induces DNA damage, its efficacy is limited by intrinsic resistance mechanisms, leading to tumor relapse. In this study we aimed to identify microRNA-mediated resistance mechanisms.

Methods

MicroRNA screens were performed to identify temozolomide resistance mechanisms. Temozolomide response was evaluated using clonogenic and spheroid assays in glioblastoma cell lines and patient-derived primary cells. DNA damage response was assessed by γH2AX foci formation. Cell cycle distribution, senescence and ferroptosis were assessed following miR-19b attenuation. An orthotopic xenograft and a syngeneic mouse model were used to confirm findings.

Results

Our screen and subsequent phosphoprotein analysis identified miR-19b and its target PPP2R5E, a subunit of the phosphatase PP2A, as modulators of temozolomide response. Attenuation of miR-19b upregulated PPP2R5E, inducing genotoxic stress, thereby enhancing temozolomide response. Mechanistically, DNA damage correlated with elevated nuclear ROS, promoting senescence and ferroptosis. Consistently, pharmacological activation of PP2A with FTY720 phenocopied the effects of miR-19b suppression. Conversely, knockdown of PPP2R5E reversed temozolomide sensitisation in vitro, in vivo, and ex vivo models, confirming the critical role of the miR-19b/PPP2R5E axis in modulating drug response.

Conclusions

Therapeutic targeting of the PPP2R5E/PP2A complexes holds promise for enhanced temozolomide efficacy in glioblastoma.